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Abstract
Introduction We performed 4-year follow-up neuropsychological assessment to investigate cognitive decline and the prog-
nostic abilities from presymptomatic to symptomatic familial frontotemporal dementia (FTD).
Methods Presymptomatic MAPT (n = 15) and GRN mutation carriers (n = 31), and healthy controls (n = 39) underwent 
neuropsychological assessment every 2 years. Eight mutation carriers (5 MAPT, 3 GRN) became symptomatic. We investi-
gated cognitive decline with multilevel regression modeling; the prognostic performance was assessed with ROC analyses 
and stepwise logistic regression.
Results MAPT converters declined on language, attention, executive function, social cognition, and memory, and GRN 
converters declined on attention and executive function (p < 0.05). Cognitive decline in ScreeLing phonology (p = 0.046) 
and letter fluency (p = 0.046) were predictive for conversion to non-fluent variant PPA, and decline on categorical fluency 
(p = 0.025) for an underlying MAPT mutation.
Discussion Using longitudinal neuropsychological assessment, we detected a mutation-specific pattern of cognitive decline, 
potentially suggesting prognostic value of neuropsychological trajectories in conversion to symptomatic FTD.
Keywords Presymptomatic · Frontotemporal dementia · Familial · Biomarkers · Cognition · Neuropsychological 
assessment · Longitudinal
Introduction
Frontotemporal dementia (FTD) is a presenile neurodegen-
erative disorder, leading to a heterogeneous clinical pres-
entation, involving behavioural (behavioural variant FTD; 
bvFTD) and/or language deterioration (primary progressive 
aphasia; PPA) [1]. FTD has an autosomal dominant pattern 
of inheritance in 30 percent of cases, with mutations in the 
progranulin (GRN) and microtubule-associated protein tau 
(MAPT) genes as its two main causes [2]. The cognitive 
profile of FTD varies depending on the clinical phenotype 
and the underlying genotype. Patients with bvFTD are 
characterized by deficits in executive function, social cog-
nition and language, whereas memory and visuoconstruction 
are initially spared [3–5]. Non-fluent variant PPA (nfvPPA) 
patients show agrammatism and speech sound distortions, 
while semantic variant PPA (svPPA) patients experience def-
icits in confrontation naming and word comprehension [6]. 
GRN mutations often lead to a clinical diagnosis of bvFTD, 
nfvPPA or parkinsonism. In MAPT mutations, bvFTD is the 
main phenotype, and semantic and memory impairments can 
be prominent neuropsychological symptoms [7].
Research in familial FTD has demonstrated the presence 
of a presymptomatic stage in which subtle cognitive changes 
have been identified [8–12]. More specifically, cognitive 
decline can start as early as 8 years prior to estimated symp-
tom onset and shows mutation-specific patterns, with GRN 
mutation carriers declining in memory, and MAPT mutation 
carriers declining in language, social cognition and memory 
[8, 10]. This suggests that cognitive measures could function 
as disease-tracking biomarkers in the presymptomatic stage. 
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However, it is currently unknown what the long-term cogni-
tive profiles of presymptomatic FTD mutations are, whether 
neuropsychological assessment can be used to track disease 
progression to the symptomatic stage, and what the prognos-
tic value is of cognitive trajectories in the presymptomatic 
and early symptomatic stage of FTD.
In this study, we investigated longitudinal cognitive 
decline on neuropsychological assessment in presympto-
matic mutation carriers (MAPT or GRN) and controls from 
the same families within our longitudinal presymptomatic 
Dutch familial FTD Risk Cohort (FTD-RisC). Second, we 
assessed the difference in cognitive course between convert-
ers’ genotypes (i.e. MAPT vs. GRN) and phenotypes (i.e. 
bvFTD vs. nfvPPA) versus non-converters. Lastly, we inves-
tigated the prognostic value of neuropsychological trajecto-
ries in predicting symptom onset within 2–4 years.
Methods
Participants
In FTD-RisC, we follow healthy 50% at-risk family mem-
bers from genetic FTD families on a 2-year basis. In the 
current study, we included 87 participants from MAPT or 
GRN families with study entries between December 2009 
and January 2013 [8, 9, 13]. The follow-up period was 
4 years, in which we acquired neuropsychological assess-
ments at study entry, follow-up after 2 years and follow-up 
after 4 years. DNA genotyping (see “Procedure”) assigned 
participants either to the presymptomatic mutation carrier 
(n = 46; 31 GRN, 15 MAPT), or control group (n = 39; 29 
GRN, 10 MAPT family members). We excluded two controls 
as they had cognitive disorders (≥ 2 SD below mean) on 
multiple domains, ultimately including 85 participants (46 
mutation carriers, 37 controls; Fig. 1).
Standard protocol approvals, registrations, 
and patient consents
Clinical investigators were blind for participants’ genetic sta-
tus if they had not undergone predictive testing. In case of 
conversion to clinical FTD, we offered the patient and family 
members genetic counselling and unblinding of genetic sta-
tus, to confirm the presence of the pathogenic mutation. At 
study entry, all participants gave written informed consent. 
The study was approved by the Medical and Ethical Review 
Committee of the Erasmus Medical Center.
Procedure
Every 2  years, participants underwent a standardized 
assessment consisting of a neuropsychological test battery, 
neurological examination, and MR imaging of the brain. 
DNA sequencing was performed at study entry. All par-
ticipants were asymptomatic according to established 
diagnostic criteria for bvFTD [3] or PPA [6] at baseline. 
Knowledgeable informants were asked about cognitive and/
or behavioural deterioration at each study visit by means 
of a structured interview and a well-validated questionnaire 
(Neuropsychiatric Inventory; NPI) [14].
Converters
Eight mutation carriers became symptomatic within the 
study time window (“converters”). Symptom onset was 
determined by means of the above mentioned assessment 
(anamnesis, MR imaging of the brain, neuropsychological 
assessment, heteroanamnestic information and unblinding 
of genetic status). Conversion was determined in a multi-
disciplinary consensus meeting of the Erasmus MC FTD 
Expertise Centre, involving neurologists (LDK, JCvsS), 
Fig. 1  Participant in- and exclusion and sample size per time point. 
Two controls were excluded as they had multiple cognitive disorders 
(≤ 2 SD below reference mean) on neuropsychological testing. Eight 
mutation carriers converted to clinical FTD within the study window. 
Their data were restructured, so that there were three time points: 
4  years before symptom onset, 2  years before symptom onset and 
symptom onset. Four years before symptom onset, only data of six 
converters were available, as two mutation carriers converted between 
baseline and first follow-up. The data of converters were compared 
to, respectively, baseline, follow-up after 2 years and follow-up after 
4 years in non-converters and healthy controls
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neuropsychologists (LCJ, JLP, SF, EvdB, JMP), medical 
doctors (LHM, ELvdE), as well as neuroradiologists, geri-
atricians, a clinical geneticist (RvM), and a care consultant. 
Six converters (5 MAPT, 1 GRN) presented with progres-
sive behaviour deterioration, functional decline, and frontal 
and/or temporal lobe atrophy on MRI, fulfilling the interna-
tional diagnostic consensus criteria of Rascovsky et al. [3] 
for bvFTD with definite FTLD pathology. Two converters 
(both GRN) presented with isolated language difficulties 
and no impairments in daily living activities, thereby fulfill-
ing the diagnostic criteria for PPA of Gorno-Tempini et al. 
[6]. Both developed nfvPPA, as they showed a non-fluent, 
halting speech, with sound errors and agrammatism. See 
Supplementary Table 1 for demographic, clinical and neu-
ropsychological data of the converters. We defined mutation 
carriers remaining without FTD symptoms as non-convert-
ers (n = 38; 28 GRN, 10 MAPT).
Neuropsychological assessment
We screened global cognitive functioning by means of the 
Mini-Mental State Examination [15] (MMSE) and frontal 
assessment battery [16] (FAB). Experienced neuropsycholo-
gists (LCJ, JLP, SF) administered neuropsychological tests 
within six cognitive domains: language, attention and mental 
processing speed, executive functioning, social cognition, 
memory, and visuoconstruction. We rated language with the 
60-item Boston Naming Test (BNT) [17], verbal Semantic 
Association Test (SAT) [18], ScreeLing phonology [19], and 
categorical fluency [20]. We assessed attention and mental 
processing speed by means of Trail making Test (TMT)-A 
[21], Stroop Color-Word Test I and II [22], Wechsler Adult 
Intelligence Scale III (WAIS-III) Digit Span forwards [23], 
and Letter Digit Substitution Test (LDST) [24]. Execu-
tive functioning was evaluated using TMT-B [21], Stroop 
Color-Word Test III [22], WAIS-III Digit Span backwards 
[23], modified Wisconsin Card Sorting Test (WCST) con-
cepts [25], letter fluency [20], and WAIS-III Similarities 
[23]. Happé cartoons [26] and Ekman Faces [27] measured 
social cognition. We assessed memory using the Dutch Rey 
Auditory Verbal Learning Test (RAVLT) [28] and Visual 
Association Test (VAT) [29]. We evaluated visuoconstruc-
tion by means of clock drawing [30] and WAIS-III Block 
Design [23]. Alternate forms were used at follow-up visits, 
when applicable (letter fluency, RAVLT, VAT). Depressive 
symptoms were rated with the Beck’s Depression Inventory 
(BDI) [31].
Study design
In converters, we restructured the three original time points 
within our study window (i.e. baseline, follow-up after 
2 years, follow-up after 4 years) into the following three 
new time points (Fig. 1):
• 4 years before symptom onset: we used the data of the 
study visit 4 years before diagnosis. Analyses could were 
performed in six converters, as two (1 GRN, 1 MAPT—2 
bvFTD) developed symptoms between baseline and first 
follow-up (i.e. at 2 years follow-up), and therefore no 
data 4 years prior to symptom onset were available.
• 2 years before symptom onset: we used the data of the 
study visit 2 years before diagnosis. Analyses included 
all eight converters.
• After symptom onset: we used the data of the diagnosis 
visit. Analyses included all eight converters.
In non-converters and controls, we used the original time 
points: baseline (data were compared to “4 years before 
symptom onset” data of converters), follow-up after 2 years 
(data were compared to “2 years before symptom onset data 
of converters) and follow-up after 4 years (data were com-
pared to “after symptom onset data of converters).
Statistical analysis
Statistical analyses were performed using SPSS Statistics 
21.0 (IBM Corp., Armonk, NY) and GraphPad Prism 7 
(La Jolla, California, USA), with the significance level at 
p < 0.05 (two-tailed) across all comparisons. We compared 
demographic data between MAPT mutation carriers, GRN 
mutation carriers and controls, and between converters, non-
converters and controls by means of one-way ANOVAs. We 
performed Pearson Χ2 tests to investigate differences in sex. 
Longitudinal comparisons of clinical data were performed 
with repeated measures ANOVAs. We standardized all raw 
neuropsychological test scores by converting them into 
z-scores (i.e. individual test score minus the baseline mean 
of the controls, divided by the baseline SD of the controls) 
per time point, after which we calculated composite z-scores 
for the respective six cognitive domains by averaging the 
z-scores of the individual tests per domain. For the longi-
tudinal comparisons we used multilevel linear regression 
modeling. This analysis corrects for bias when data absence 
is dependent on characteristics present in the model, and 
can therefore efficiently handle missing and unbalanced time 
points. There were two levels in the models: the partici-
pants constituted the upper level; their repeated measures the 
lower level. We ran two analyses to assess cognitive decline 
per mutation (1) and clinical status (2):
1. We entered mutation status (MAPT mutation carrier, 
GRN mutation carrier or control), time (4 years before 
symptom onset, 2 years before symptom onset, and after 
symptom onset), and first-order interactions, with age, 
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gender and educational level as covariates. We reran the 
analyses excluding the converters to exclude convert-
ers driving the cognitive decline in the mutation carrier 
groups;
2. We split the converter group according to genotype 
(MAPT or GRN) and phenotype (bvFTD or nfvPPA) 
to investigate specific profiles of cognitive decline over 
time. We then entered clinical status (converter, non-
converter or control), time, and first-order interactions, 
with age, gender and educational level as covariates.
Third, to investigate the prognostic abilities of cognitive 
decline in discriminating between converters and non-con-
verters, we determined the area under the curve (AUC) by 
receiver operating characteristic (ROC) analyses on the neu-
ropsychological trajectories between visits. For this, we cal-
culated deltas between test scores; one between 4 and 2 years 
before symptom onset and one between 2 years before symp-
tom onset and symptom onset. Optimal cut-off levels were 
given by the highest Youden’s index [32]. Again, we split the 
converter group according to genotype (MAPT or GRN) and 
phenotype (bvFTD or nfvPPA). Next, we performed logistic 
regression analyses, taking group (converter vs. non-con-
verter) as the dependent variable and the deltas (tests with 
significant diagnostic performance in abovementioned ROC 
analyses) as the independent variables. The models were 
selected with a forward stepwise method according to the 
likelihood ratio test and applying the standard p values for 
variable inclusion (0.05) and exclusion (0.10), with age, sex 
and education as covariates. Goodness of fit was evaluated 
with the HL Χ2 test. Nagelkerke R2 is reported as measure of 
effect size. We checked predictor variables for multicollin-
earity. All models were corrected for multiple comparisons 
(Bonferroni).
Results
Demographics
MAPT mutation carriers were significantly younger than 
GRN mutation carriers (p = 0.012; Table 1). The mean 
familial symptom onset age was lower in MAPT than in 
GRN mutation carriers and controls (both p < 0.001). There 
were no significant differences between groups regarding 
estimated years to symptom onset (p > 0.05). Longitudinal 
analyses demonstrated that MAPT mutation carriers declined 
significantly more than GRN mutation carriers and controls 
with regards to the MMSE (p = 0.014), and also developed 
more depressive symptoms (p = 0.028). FAB and NPI scores 
did not significantly change over time (p > 0.05). Convert-
ers, non-converters and controls did not differ regarding 
demographic variables, apart from a younger family onset 
in MAPT converters than GRN converters (p = 0.043) and 
non-converters (p = 0.001; Table 1). Both MAPT and GRN 
converters declined significantly with respect to MMSE 
score (p < 0.001) and they developed more neuropsychi-
atric symptoms in the form of higher BDI (p = 0.001) and 
NPI (p = 0.021) scores in comparison to non-converters and 
controls. FAB scores did not significantly change over time 
(p > 0.05).
Longitudinal cognitive decline in MAPT and GRN 
mutation carriers
The whole group of MAPT mutation carriers declined sig-
nificantly within the domains language, social cognition and 
memory compared with controls (Table 2; Fig. 1). This was 
reflected in lower scores on the BNT and categorical fluency, 
Happé cartoons, VAT and RAVLT delayed recall (Table 2). 
In the whole group of GRN mutation carriers, no longitu-
dinal decline was found in comparison to controls. In com-
parison to GRN mutation carriers, MAPT mutation carriers 
declined significantly on the domains language (β = − 0.015, 
p < 0.001) and memory (β = − 0.016, p = 0.008), reflected 
in lower BNT (β = − 0.085, p = 0.01), SAT (β = − 0.027, 
p = 0.015), category fluency (β = − 0.107, p = 0.002), and 
RAVLT delayed recall (β = − 0.047, p = 0.001) scores. There 
were no cognitive domains or tests on which GRN muta-
tion carriers declined more than MAPT mutation carriers 
(Table 2). By excluding the five MAPT converters from 
the analyses, none of the domain scores in MAPT mutation 
carriers continued to show significant decline over time in 
comparison to controls. Regarding individual tests, however, 
the decline on the RAVLT delayed recall remained signifi-
cant (β = − 0.032, p = 0.023). The results did not change by 
excluding the three GRN converters from the analyses. In 
comparison to GRN, MAPT mutation carriers still declined 
more on language (β = − 0.010, p = 0.004), reflected in lower 
ScreeLing phonology (β = − 0.008, p = 0.024) and category 
fluency (β = − 0.007, p = 0.041). There was no cognitive 
decline in controls—but significant improvement was found 
on social cognition (Happé non-ToM and Ekman Faces) and 
memory (RAVLT immediate and delayed recall) (Table 2). 
The raw neuropsychological test scores per time point can 
be found in Supplementary Table 2.
Longitudinal cognitive decline in converters 
and non‑converters
Converters with a MAPT mutation deteriorated significantly 
on all domains but visuoconstruction (Fig. 2a–d, f; Table 3). 
Within these domains, performances declined on BNT 
(p < 0.001), LDST (p = 0.035), Stroop I, II and III (I: p = 0.017; 
II: p < 0.001; III: p = 0.021), categorical fluency (p = 0.001), 
WAIS similarities (p < 0.001), Happé ToM (p = 0.011), and 
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RAVLT immediate (p = 0.004) and delayed recall (p = 0.030). 
Converters with a GRN mutation deteriorated significantly on 
attention and mental processing speed, and executive function 
(Fig. 2b, c; Table 3). Within these domains, performances on 
TMT-B (p < 0.001), Stroop III (p < 0.001), WCST (p = 0.005), 
letter fluency (p = 0.012) and WAIS similarities (p < 0.001) 
deteriorated significantly over time. Converters with bvFTD 
had a similar pattern of cognitive decline as MAPT convert-
ers, with lower scores on social cognition, memory, language, 
attention and executive function (Table 3). Comparably, con-
verters with nfvPPA had a similar pattern of cognitive decline 
as GRN converters, with lower scores on attention and execu-
tive function (Table 3). There were no differences in decline 
between converters with bvFTD and nfvPPA (Table 3). The 
raw neuropsychological test scores per time point can be found 
in Supplementary Table 3.
Classification between converters 
and non‑converters
Between 4 and 2 years before symptom onset, the delta 
domain and individual neuropsychological test scores 
Table 1  Demographics and clinical data
Values indicate: mean ± standard deviation. Significant comparisons are displayed in bold
GRN progranulin, HC healthy control, MMSE Mini-Mental State Examination, FAB frontal assessment battery, BDI Beck’s depression inven-
tory, NPI neuropsychiatric inventory
*p value represents result of overall ANOVA between MAPT mutation carriers, GRN mutation carriers and healthy controls
**p value represents result of overall ANOVA between MAPT converters, GRN converters, non-converters and HC
a Significant post hoc test between MAPT and GRN mutation carriers
b Significant post hoc test between MAPT mutation carriers and healthy controls
c Significant post hoc test between converters and non-converters
d Significant post hoc test between converters and healthy controls
e Only data of MAPT converters available, therefore the p value represents the comparison between MAPT converters, non-converters and HC
f Dutch educational system categorized into levels from 1 = less than 6 years of primary education to 7 = academic schooling (Verhage, 1964)
g Data only available on follow-up visits
Demographics HC (n = 39) MAPT carriers 
(n = 15)
GRN carriers 
(n = 31)
p value* MAPT 
converters 
(n = 5)
GRN converters 
(n = 3)
Non-converters 
(n = 38)
p value**
Age at study 
entry, years
49.1 ± 12.2 41.9 ± 10.0 52.1 ± 8.2 0.012a 45.3 ± 8.5 54.9 ± 9.0 48.8 ± 10.3 0.704
Sex, female (%) 20 (56%) 7 (47%) 20 (65%) 0.506 1 (20%) 3 (100%) 23 (60.5%) 0.154
Education 
(Verhage)f
5.2 ± 1.0 5.1 ± 1.6 5.7 ± 0.9 0.102 6.0 ± 0.7 5.7 ± 0.6 5.4 ± 1.3 0.409
Onset age fam-
ily, years
59.0 ± 5.8 51.3 ± 6.7 61.0 ± 2.4 < 0.001a,b 48.0 ± 4.7 59.7 ± 0.0 58.8 ± 6.1 0.002c,d
Estimated years 
to onset, years
− 10.2 ± 11.2 − 7.7 ± 9.6 − 9.4 ± 7.9 0.690 − 2.7 ± 4.0 − 4.8 ± 9.0 − 10.0 ± 8.5 0.335
Clinical 
data
Years 
to 
onset
HC (n = 39) MAPT carriers 
(n = 15)
GRN carriers 
(n = 31)
p value* MAPT 
converters 
(n = 5)
GRN converters 
(n = 3)
Non-converters 
(n = 38)
p value**
MMSE 4 29.1 ± 1.3 29.6 ± 0.5 29.1 ± 1.6 0.451 29.5 ± 0.6 29.0 ± 1.4 29.2 ± 1.4 0.924
2 29.2 ± 1.3 28.7 ± 2.2 28.9 ± 1.6 0.513 29.8 ± 0.4 28.0 ± 1.0 27.7 ± 1.5 0.271
0 29.2 ± 1.0 28.4 ± 1.5 29.2 ± 1.4 0.099 27.2 ± 1.6 27.7 ± 1.5 29.3 ± 1.2 0.001c,d
FABg 4 – – – – – – – –
2 17.4 ± 0.9 17.4 ± 0.8 17.5 ± 0.9 0.883 17.3 ± 1.0 17.5 ± 0.7 17.5 ± 0.9 0.929
0 16.7 ± 1.7 16.5 ± 1.6 17.0 ± 1.1 0.639 15.4 ± 1.5 16.3 ± 1.5 17.1 ± 1.1 0.120
BDI 4 4.1 ± 4.5 4.0 ± 6.3 3.2 ± 3.9 0.693 1.3 ± 1.0 2.0 ± 2.8 3.7 ± 5.0 0.645
2 3.7 ± 3.9 4.5 ± 5.0 3.2 ± 4.0 0.638 5.0 ± 4.7 2.7 ± 3.8 3.5 ± 4.4 0.866
0 3.5 ± 4.3 7.6 ± 9.5 3.0 ± 6.7 0.108 11.6 ± 13.0 6.3 ± 5.1 3.1 ± 6.5 0.042c,d
NPI 4 0.1 ± 0.5 4.6 ± 11.2 1.4 ± 3.4 0.180 0.0 ± 0.0 – 3.0 ± 7.5 0.006c–e
2 0.6 ± 1.2 6.4 ± 20.7 0.3 ± 0.7 0.095 0.2 ± 0.4 0.0 ± 0.0 2.9 ± 13.3 0.767
0 0.8 ± 1.5 12.3 ± 18.7 2.1 ± 6.6 0.001a,b 15.6 ± 16.3 10.7 ± 15.9 3.4 ± 11.4 0.009d
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failed to distinguish significantly between converters and 
non-converters. Between 2 years before symptom onset and 
symptom onset decline on categorical fluency was predic-
tive of an underlying MAPT mutation (p = 0.025; Table 4). 
Decline on ScreeLing phonology (p = 0.046) and letter flu-
ency (p = 0.046) was predictive of conversion to nfvPPA 
(Table 4).
Discussion
This study examined a large cohort of at-risk participants 
from GRN and MAPT FTD families by means of neuropsy-
chological assessment during a 4-year follow-up. Within the 
study time window, eight mutation carriers became symp-
tomatic. Converters with a MAPT and GRN mutation had 
mutual as well as gene-specific profiles of cognitive decline. 
Table 2  Cognitive trajectories in mutation carriers (converters, non-converters) and healthy controls
Values indicate: mean ± standard deviation; β represents estimate of change over time. Composite domain scores are z-scores, individual test 
scores are raw scores. Composite domain scores are expressed as z-scores, the individual test scores are raw scores. p values represent compari-
sons to healthy controls. Significant comparisons are displayed in bold
MAPT microtubule-associated protein tau, GRN progranulin, BNT Boston Naming Test, SAT semantic association test, TMT Trail making Test, 
WAIS Wechsler Adult Intelligence Scale, LDST letter digit substitution test, WCST Wisconsin card sorting test, ToM theory of mind, VAT visual 
association test, RAVLT Rey Auditory Verbal Learning Test, imm immediate, del delayed
a Remained significant after excluding converters from the analyses
b Survived Bonferroni correction for multiple comparisons
c Higher scores and β weights indicate worse performance
Domain test Healthy controls (n = 39) MAPT mutation carriers (n = 15) GRN mutation carriers (n = 31)
Baseline β p Baseline β p Baseline β p
Language 0.0 ± 0.6 0.000 0.931 0.2 ± 0.6 − 0.010 0.002 0.1 ± 0.7 0.004 0.121
BNT 53.4 ± 4.5 0.026 0.105 52.6 ± 5.3 − 0.080 0.005 55.1 ± 3.7 0.006 0.786
SAT 27.8 ± 1.1 − 0.003 0.604 27.9 ± 1.5 − 0.008 0.604 27.5 ± 2.0 0.019 0.033a
ScreeLing phonology 23.5 ± 0.8 0.001 0.733 23.9 ± 0.3 − 0.005 0.190 23.8 ± 0.5 − 0.001 0.863
Categorical fluency 23.9 ± 4.9 0.026 0.141 26.5 ± 6.6 − 0.087 0.006 23.4 ± 5.7 0.021 0.424
Attention and processing speed 0.0 ± 0.8 − 0.001 0.084 0.3 ± 0.6 − 0.003 0.096 0.1 ± 0.9 − 0.003 0.075
TMT part  Ac 31.8 ± 15.0 − 0.022 0.416 26.1 ± 9.7 0.065 0.192 31.4 ± 12.2 0.060 0.145
Stroop card  Ic 47.1 ± 8.0 0.039 0.011 43.2 ± 8.8 − 0.017 0.529 45.0 ± 8.4 − 0.001 0.951
Stroop card  IIc 58.5 ± 10.6 0.012 0.539 54.9 ± 8.5 0.027 0.470 60.2 ± 13.2 0.001 0.969
Digit Span forwards 8.7 ± 1.9 0.001 0.871 9.0 ± 2.6 − 0.010 0.294 9.4 ± 2.4 − 0.016 0.055
LDST 34.5 ± 6.8 0.001 0.894 34.2 ± 4.7 − 0.636 0.699 33.2 ± 7.4 0.005 0.798
Executive function 0.0 ± 0.7 0.001 0.505 0.3 ± 0.6 − 0.005 0.065 0.2 ± 0.8 − 0.004 0.052
TMT part  Bc 67.8 ± 29.3 0.052 0.494 61.0 ± 28.5 0.079 0.570 72.2 ± 42.7 − 0.099 0.390
Stroop card  IIIc 93.7 ± 22.6 − 0.087 0.021 83.8 ± 14.7 0.141 0.042 96.6 ± 26.2 0.013 0.815
Digit span backwards 6.1 ± 2.0 0.008 0.194 6.6 ± 1.8 0.002 0.877 6.6 ± 2.1 − 0.011 0.222
WCST concepts 5.5 ± 0.9 0.002 0.592 5.6 ± 1.1 − 0.009 0.296 5.80 ± 0.6 − 0.010 0.144
Letter fluency 32.1 ± 9.9 0.134 < 0.001b 36.1 ± 14.3 − 0.108 0.049 38.9 ± 12.0 − 0.062 0.173
Similarities 24.8 ± 4.7 0.006 0.645 25.5 ± 4.7 − 0.034 0.122 26.2 ± 5.0 − 0.011 0.556
Social cognition 0.0 ± 0.8 0.000 0.878 0.2 ± 0.7 − 0.009 0.007 0.3 ± 0.7 − 0.003 0.332
Happé ToM 11.8 ± 3.4 0.013 0.172 12.6 ± 3.7 − 0.044 0.011 12.9 ± 2.9 − 0.005 0.707
Happé non-Tom 11.7 ± 2.9 0.020 0.013 12.4 ± 2.8 − 0.036 0.017 13.0 ± 2.6 − 0.012 0.331
Ekman faces 45.7 ± 6.4 0.038 0.009 47.0 ± 5.5 − 0.028 0.293 47.10 ± 5.5 − 0.013 0.548
Memory 0.0 ± 0.7 0.000 0.848 0.1 ± 1.3 − 0.017 < 0.001b 0.1 ± 0.9 − 0.001 0.745
VAT 11.8 ± 0.6 0.001 0.740 11.4 ± 1.6 − 0.012 0.019 11.5 ± 0.9 0.000 0.926
RAVLT imm. recall 42.6 ± 9.8 0.157 < 0.001b 47.5 ± 9.7 − 0.076 0.090 46.3 ± 10.6 − 0.015 0.686
RAVLT del. recall 8.4 ± 3.2 0.050 < 0.001b 9.7 ± 3.9 − 0.048 < 0.001a,b 9.4 ± 3.3 − 0.000 0.983
RAVLT recognition 28.6 ± 2.1 0.014 0.127 29.0 ± 2.0 − 0.022 0.176 29.2 ± 1.2 − 0.009 0.505
Visuoconstruction 0.0 ± 0.8 − 0.001 0.656 − 0.2 ± 0.7 − 0.005 0.266 0.0 ± 1.0 0.000 0.963
Block design 36.5 ± 14.0 0.034 0.305 35.5 ± 20.8 − 0.006 0.917 39.3 ± 18.5 − 1.164 0.246
Clock drawing 12.6 ± 1.4 0.003 0.453 12.2 ± 1.3 − 0.009 0.284 12.4 ± 1.8 0.005 0.475
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Cognitive decline on categorical fluency between 2 years 
before conversion and symptom onset was predictive for 
an underlying MAPT mutation, and decline on ScreeLing 
phonology and letter fluency was predictive for conversion 
to nfvPPA. These results suggest that neuropsychological 
assessment could provide sensitive clinical biomarkers to 
identify and track FTD mutation carriers at-risk of convert-
ing to the symptomatic stage. These findings hold potential 
for improving early clinical diagnosis by identifying the 
most sensitive neuropsychological tests for conversion, and 
use in upcoming disease-modifying clinical trials.
Following the MAPT mutation carriers over a 4-year 
period, we found significant decline in language, social cog-
nition and memory. This is consistent with findings from 
previous presymptomatic familial FTD studies, in which 
both cross-sectional [9–11, 33] and longitudinal [8] decline 
was found. Specifically, in our first follow-up study [8], we 
demonstrated decline in the domains language, social cog-
nition and memory 5–8 years before estimated symptom 
onset. It should be taken into account that this study made 
use of estimated onset as a proxy, instead of actual symp-
tom onset as in the present study—but the similar profile 
of decline confirms the presence of early changes in these 
three domains. As in our previous study, the present results 
are largely driven by the converters. This could suggest that 
neuropsychological test scores remain static while mutation 
carriers are presymptomatic, and cognitive decline starts 
only near or at symptom onset [34–36], suggesting an explo-
sive rather than gradual start of the symptomatic disease 
stage. Alternatively, we might be unable to pick up subtle 
cognitive changes in presymptomatic mutation carriers due 
to lack of power. Also, although well-validated, most of our 
neuropsychological tests were not developed for repeated 
administration in a preclinical population [37]. We there-
fore cannot rule out that familiarity and/or practice effects 
are obscuring subtle cognitive decline, a notion that seems 
to be underwritten by improvement in social cognition and 
memory in controls, but not mutation carriers.
In our exploratory analyses in converters, we discovered 
both common as well as mutation-specific profiles of cogni-
tive decline in MAPT and GRN. In both mutations, decline 
in attention, mental processing speed and executive function 
was found—while only converters with a MAPT mutation 
demonstrated decline on language, memory and social cogni-
tion. Previous studies in familial FTD also point to distinct 
profiles for MAPT and GRN [8, 10–12], and are largely con-
sistent with our present findings. Another important aspect is 
the longitudinal tracking of the different clinical phenotypes. 
The similar patterns of cognitive decline in bvFTD as MAPT, 
and nfvPPA as GRN are related to the dominant genotype in 
Fig. 2  Multilevel linear regression model displaying longitudi-
nal decline (4 years, 2 years and after symptom onset) in composite 
domain z-score in the total group of converters (light green), MAPT 
converters (light blue dotted line), GRN converters (dark blue dotted 
line), non-converters (dark green) and healthy controls (black). Mod-
els are displayed per cognitive domain: a social cognition, b atten-
tion and mental processing speed, c executive functioning, d memory, 
e visuoconstruction, and f language. NB: the healthy controls have a 
mean z-score of zero by default as the z-scores of mutation carriers 
were based on that (raw score minus mean score of healthy controls, 
divided by the standard deviation of healthy controls). MAPT micro-
tubule-associated protein tau, GRN progranulin
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each group (e.g. all nfvPPA converters have a GRN muta-
tion). These findings suggest that neuropsychological assess-
ment can be used to track the different mutations and phe-
notypes from the presymptomatic to the symptomatic stage, 
which is advantageous considering the need for good clinical 
endpoints in future disease-modifying trials.
Extending the findings from our first follow-up study [8], 
we demonstrated significant decline on the RAVLT recall in 
presymptomatic MAPT mutation carriers. The additional finding 
that lower memory scores over time were also found in MAPT, 
and not GRN converters—suggesting a mutation-specific 
aetiology—corroborate this. Although memory loss has been 
described in GRN [38, 39], this is usually a later symptom, while 
episodic memory impairment has been found as the presenting 
and most prominent symptom in MAPT [7, 40, 41]. Interest-
ingly, the Genetic Frontotemporal dementia Initiative (GENFI) 
consortium revealed hippocampal atrophy in presymptomatic 
MAPT from 15 years before estimated symptom onset [10], and 
as this medial temporal structure is critical for episodic memory 
processing [42] this offers a good explanation for our findings. 
In line with earlier studies [42, 43], we did find deficits in verbal 
recall but not visual associative memory. Semantically loaded 
tasks such as the RAVLT can be particularly more difficult than 
visual memory tasks like the VAT, as a result of the prominent 
semantic impairments seen early in MAPT-associated FTD [44]. 
Our results contribute to the present thinking that memory defi-
cits can be an integral part of the clinical spectrum [42], and 
comprehensive memory tasks should therefore be incorporated 
in the standard diagnostic work-up.
Knowing the cognitive profile of decline indicative for con-
version is important to get more insight into the timing of clini-
cal changes in the earliest disease stage. We found that conver-
sion can be predicted based on cognitive decline in the 2 years 
prior to symptom onset, but not earlier. As the cognitive decline 
was part of the diagnostic process of determining conversion, 
this is not a surprising finding. However, it does suggest a more 
explosive disease development with cognitive decline acceler-
ating rapidly in proximity of symptom onset, which is in line 
with evidence from a large familial Alzheimer’s disease cohort 
[45]. By selectively choosing tests within the domains that 
have prognostic abilities, the neuropsychological battery can 
be shortened, which would benefit patient burden and helps 
cutting healthcare expenses. Especially fluency tasks seem to 
be promising candidates, as they were able to distinguish accu-
rately between future phenotype and underlying genotype. The 
latter is essential for patient stratification in future clinical trials 
targeting specific pathologies, and ideally these interventions 
should be applied in the presymptomatic stage [46]. Reliable 
phenotypic prediction furthermore optimizes the diagnostic 
process by shortening the current diagnostic delay [47], and 
is helpful for the patient, caregiver and clinician in knowing 
what disease presentation and course to expect. Verbal fluency 
tests are widely used in dementia diagnosis setting [48], and 
are affected in both presymptomatic [8, 11] and symptomatic 
FTD [49, 50]. Future research could additionally investigate the 
use of qualitative assessment of verbal fluency (e.g. clustering, 
switching between clusters), as recent research [49] points to 
differences between FTD and PPA subtypes—making this a 
promising application of verbal fluency for a precise clinical 
differentiation in presymptomatic and early stage FTD.
Key strengths of our study constitute our longitudinal design, 
spanning a 4-year follow-up of at-risk participants from both MAPT 
and GRN families. Although our group of converters is currently 
small, this is the first study tracking FTD mutation carriers from 
the presymptomatic to symptomatic disease stage. Being aware of 
the caveats of small sample sizes and administering a large amount 
of neuropsychological tests with respect to statistical power, our 
results warrant replication in our cohort as well as larger interna-
tional cohorts such as GENFI [10], in which with the passing of 
time more mutation carriers will approach symptom onset and/
or convert to clinical FTD. The dropout rate is very low, creating 
balanced datasets across the three time points. Additionally, use of 
multilevel linear modeling further handles efficiently with miss-
ing data. Directions for future research entail the development of 
neuropsychological tasks more suited to administer in the presymp-
tomatic phase (robust to ceiling effects) and repeated administra-
tion (robust to practice and able to measure small changes). More 
extensive quantification tools of behavioural functioning are also 
needed to capture the entire clinical spectrum of (presymptomatic) 
FTD, as well as assessment methods that rely less on the accuracy 
of informant report [37]. A disadvantage of the study is the fact that 
the neuropsychological assessment was part of the clinical assess-
ment with which we determined conversion to the symptomatic 
stage. This has likely led to a circular reasoning, as we demonstrated 
that converters declined over time, while cognitive decline was con-
sidered a prerequisite for conversion. Ideally, the tests assessed in 
our study should not have been used in the diagnosis of conver-
sion. However, in our multidisciplinary meeting, we followed the 
international consensus criteria for bvFTD [3] and PPA [6], using 
all available clinical information—e.g. MR imaging of the brain, 
anamnestic and heteroanamnestic information, behavioural and 
neuropsychiatric questionnaires, unblinding of genetic status—so 
that symptom onset did not solely depend on the neuropsychologi-
cal assessment. Furthermore, as the multilevel model assumes a 
linear relationship between genetic status and cognitive decline over 
time, we could have missed non-linear effects over time. Lastly, the 
analyses on the non-converters and controls were performed using 
the original baseline and follow-up visits, regardless of, e.g. age and 
time to estimated symptom onset. It is possible that these analyses 
therefore lost some sensitivity to detect cognitive decline over time. 
However, as between-group analyses on age and estimated years to 
symptom onset in converters, non-converters, and controls did not 
show significant differences (respectively, p = 0.99 and p = 0.19), 
we believe this effect is minimal.
Our study investigates longitudinal neuropsychological per-
formance in a large cohort of at-risk individuals from genetic 
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FTD families. We provide evidence of mutation-specific cog-
nitive decline when moving from the presymptomatic into 
symptomatic stage, and of neuropsychological trajectories 
predicting symptom onset. These results suggest the potential 
biomarker value of neuropsychological assessment in both 
disease-monitoring and predicting conversion to clinical FTD.
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